These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16797593)

  • 1. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M; Klepac N
    J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in body weight after pramipexole treatment in Parkinson's disease.
    Kumru H; Santamaria J; Valldeoriola F; Marti MJ; Tolosa E
    Mov Disord; 2006 Nov; 21(11):1972-4. PubMed ID: 16972276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
    Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
    Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semantic activation in Parkinson's disease patients on and off levodopa.
    Angwin AJ; Arnott WL; Copland DA; Haire MP; Murdoch BE; Silburn PA; Chenery HJ
    Cortex; 2009 Sep; 45(8):950-9. PubMed ID: 19356748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    De Reuck J; De Weweire M; Van Maele G; Santens P
    J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor procedural learning in Parkinson's disease.
    Muslimovic D; Post B; Speelman JD; Schmand B
    Brain; 2007 Nov; 130(Pt 11):2887-97. PubMed ID: 17855374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and motor components of response speed in the stroop test in Parkinson's disease patients.
    Hsieh YH; Chen KJ; Wang CC; Lai CL
    Kaohsiung J Med Sci; 2008 Apr; 24(4):197-203. PubMed ID: 18424356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of levodopa on cognition of idiopathic Parkinson's disease].
    Alonso-Prieto E; Michel-Esteban E; Trujillo-Matienzo C; Palmero-Soler E
    Neurologia; 2004 Dec; 19(10):710-8. PubMed ID: 15568168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa and executive performance in Parkinson's disease: a randomized study.
    Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
    J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.